Mesa Laboratories Inc. Advanced Charts | MLAB
This article provides advanced chart information and financial data for Mesa Laboratories Inc. (MLAB). It includes analyst ratings, key financial metrics like P/E ratio and dividend yield, and details about the company's business segments. The page also features a peer comparison and data provider information.
Mesa Laboratories stock reports 1.00 percent Q1 revenue growth
Mesa Laboratories reported a 1.00 percent year-over-year revenue growth for Q1 fiscal 2027, reaching USD 60.14 million. Despite this revenue increase, diluted EPS declined by 42.35 percent to USD 0.49. Analysts maintain an "Equal Weight" rating with a target price below the current Nasdaq quote, highlighting the importance of future earnings growth to support its valuation.
Director at Mesa Laboratories (NASDAQ: MLAB) receives new stock unit grant
Mesa Laboratories director R. Tony Tripeny was granted 1,774 time-based Restricted Stock Units (RSUs) on September 9, 2026. These RSUs will vest on September 9, 2027, increasing his equity-linked holdings in the company. The grant was not made under a Rule 10b5-1 trading plan.
MESA LABORATORIES INC /CO/ Director Tripeny R Tony Granted 1,774 Derivative Securities on September 9, 2026
MESA LABORATORIES INC /CO/ Director Tripeny R Tony was granted 1,774 derivative securities on September 9, 2026. This transaction represents 100% of Tripeny R Tony’s total derivative securities holding and is classified as an award or grant. Following this award, Tripeny R Tony holds 1,774 derivative securities in the company.
Mesa Laboratories Director Shannon Hall Granted 1,774 RSUs on September 9, 2026
Mesa Laboratories Director Shannon Hall was granted 1,774 Restricted Stock Units (RSUs) on September 9, 2026, as detailed in a Form 4 filing. These RSUs, which represent a conditional right to one share of common stock each, were granted at a price of $0 and are scheduled to vest on September 9, 2027. Following this transaction, Hall directly owns 1,774 derivative securities in the company.
Director awarded 1,774 RSUs at Mesa Laboratories (MLAB)
Mesa Laboratories (MLAB) director Shannon Hall was granted 1,774 Restricted Stock Units (RSUs) on September 9, 2026. These RSUs represent a contingent right to receive one share of common stock per unit and are scheduled to vest on September 9, 2027. This transaction results in Hall directly owning 1,774 RSUs after the award.
Mesa Laboratories (MLAB) awards stock units vesting in 2027 to a director
Mesa Laboratories (MLAB) announced that Director Mark Christopher Capone was granted 2,423 Restricted Stock Units (RSUs) on September 9, 2026. These RSUs represent a contingent right to receive one share of common stock each and are scheduled to vest on September 9, 2027. Following this grant, Mr. Capone directly holds 2,423 RSUs, increasing his equity-based compensation stake in the company.
Mesa Laboratories Announces Certified Shareholder Voting Outcomes from September 2026 Annual Meeting
Mesa Laboratories, Inc. (NASDAQ: MLAB) has released the certified results from its annual shareholder meeting held on September 8, 2026. Shareholders elected all seven nominated directors for one-year terms, ratified Baker Tilly US, LLP as the independent auditor, and approved the non-binding advisory resolution on executive compensation. The company reported a strong turnout with 4,872,692 out of 5,595,869 eligible voting shares represented.
Earnings call transcript: Mesa Laboratories posts Q1 2026 revenue miss
Mesa Laboratories reported Q1 2026 revenue of $60.1 million, missing analyst forecasts due to delivery reliability issues in its Sterilization and Disinfection Control (SDC) segment, despite overall positive organic growth. CEO Siddhartha Kadia emphasized that the SDC problem is an execution issue, not a demand problem, and the company is focused on internal fixes and strengthening the balance sheet. The company anticipates providing full-year fiscal 2027 guidance in November.
Is Mesa Laboratories Inc (MLAB) Overvalued After 4.5% Rally? GF
Mesa Laboratories Inc (MLAB) shares recently rallied 4.5%, but GuruFocus' GF Value indicates the stock is currently overvalued at $124.76, exceeding its fair value estimate of $106.27. While MLAB has a strong momentum rank and an above-average GF Score of 76/100, its growth prospects are weaker, and insider selling suggests potential reservations about its current valuation. Investors are advised to exercise caution due to the lack of a margin of safety.
Former Mesa Labs (MLAB) exec files notice for August stock sale
A former officer of Mesa Laboratories Inc (MLAB), Gary M. Owens, has filed a Rule 144 notice to sell up to 20,000 shares of common stock through Fidelity Brokerage Services LLC. The aggregate market value of these shares is approximately $2.45 million. These shares were acquired through restricted stock vesting between 2018 and 2025, and Owens previously sold 3,706 shares on June 16, 2026.
Mesa Labs director John Sullivan sells $800,090 in stock
Mesa Laboratories director John Sullivan sold 7,093 shares of common stock for $800,090, with each share priced at $112.80. The transaction occurred on August 13, 2026, and the shares were sold to Mesa’s President and CEO, Siddhartha Kadia. Following the sale, Sullivan directly holds 17,834 shares, with an additional 45,110 shares held indirectly through a family trust.
Mesa Laboratories (NASDAQ: MLAB) director now holds 6,973 shares
Mesa Laboratories director Shannon Hall acquired 2,784 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs) on August 15, 2026. This transaction increased Hall's direct common stock holding to 6,973 shares, while the derivative RSU position was reduced to zero. The Form 4 filing indicates a neutral impact and sentiment regarding this insider trading activity.
Mesa Labs director John Sullivan sells $800,090 in stock By Investing.com
John Sullivan, a director at Mesa Laboratories Inc., sold 7,093 shares of common stock for $800,090 at $112.80 per share on August 13, 2026. The shares were purchased by Mesa's President and CEO, Siddhartha Kadia, while MLAB stock is trading near its 52-week high and shows a 55% return over the past year. Following the transaction, Sullivan directly holds 17,834 shares, with an additional 45,110 shares held indirectly by a family trust.
Mesa Labs (NASDAQ: MLAB) director settles 3,810 RSUs into stock
Mesa Labs director Shiraz Shabanali Ladiwala reported the settlement of 3,810 Restricted Stock Units (RSUs) into common stock on August 15, 2026. These RSUs converted to 3,810 shares of common stock at an exercise price of $0.00 per share. Following this transaction, Ladiwala directly owns 12,333 shares of MLAB common stock.
Mesa Laboratories (NASDAQ: MLAB) director adds 2,784 shares via RSU vesting
Mesa Laboratories director Mark Christopher Capone acquired 2,784 shares of common stock through the vesting and exercise of Restricted Stock Units (RSUs) on August 15, 2026. This transaction increased his direct holdings of Mesa Laboratories common stock to 6,213 shares, while his derivative RSU position was reduced to zero. The RSUs vested at a transaction price of $0.00 per share, indicating no monetary cost for the acquisition.
Mesa Labs (NASDAQ: MLAB) director adds 2,784 shares from RSUs
Mesa Laboratories director Jennifer Sadie Alltoft acquired 2,784 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs) on August 15, 2026. This transaction resulted in Alltoft directly holding 7,662 shares of MLAB common stock, with no remaining RSUs from this specific award. The acquisition was a non-cash event at a stated price of $0.00 per share and was not executed under a Rule 10b5-1 trading plan.
Mesa Laboratories (NASDAQ: MLAB) director adds stock via RSU vesting
Mesa Laboratories director R. Tony Tripeny recently acquired 2,784 shares of common stock through the vesting of Restricted Stock Units (RSUs) on August 15, 2026. This transaction increased his direct holdings to 9,082 shares, and the RSU derivative position was reduced to zero. The Form 4 filing indicates this was a routine equity award settlement, not an open-market purchase or sale.
Diamond Hill Capital Management LLC Investment Advisor Makes New Investment in Mesa Laboratories, Inc. $MLAB
Diamond Hill Capital Management LLC initiated a new position in Mesa Laboratories (NASDAQ:MLAB) by purchasing 155,771 shares valued at approximately $15.5 million, representing 2.78% of the company. Institutional investors now own 90.6% of MLAB. Analysts maintain a "Hold" rating with an average target price of $110, following recent adjustments from Wells Fargo and Wall Street Zen.
Siddhartha Kadia Buys 7,093 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock
Mesa Laboratories CEO Siddhartha Kadia recently purchased 7,093 shares of the company's stock for approximately $800,090. Following this transaction, his total ownership increased to 7,093 shares. The company's shares rose 2.0% to $108.19, and it reported quarterly revenue of $60.14 million and earnings of $2.68 per share, along with a quarterly dividend of $0.16 per share.
R Tony Tripeny Acquires 900 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock
Director R. Tony Tripeny recently purchased 900 shares of Mesa Laboratories (NASDAQ:MLAB) stock for over $102,000, increasing his direct ownership by 16.67%. The company reported quarterly revenue of $60.14 million and earnings of $2.68 per share, with its stock trading up 2.0% to $108.19. Analysts currently maintain a "Hold" rating for MLAB with a consensus target price of $110.00.
Mesa Labs director John Sullivan sells $800,090 in stock
Mesa Laboratories director John Sullivan sold 7,093 shares of common stock for $800,090 to CEO Siddhartha Kadia on August 13, 2026. Following the transaction, Sullivan directly holds 17,834 shares, with an additional 45,110 shares held indirectly by a family trust. The sale occurred as MLAB stock trades near its 52-week high after a 55% return over the past year.
Mesa Laboratories CEO Kadia buys $800,090 in stock
Mesa Laboratories Inc.'s CEO, Siddhartha Kadia, recently purchased 7,093 shares of company stock for $800,090. This transaction occurred on August 13, 2026, at $112.80 per share, close to its 52-week high. The acquisition was made indirectly through a trust from Mesa’s Board Chair, John Sullivan, following the company's fiscal first-quarter revenue miss.
Mesa Laboratories (NASDAQ: MLAB) director sells shares to CEO
Mesa Laboratories director John James Sullivan sold 7,093 shares of common stock to President and CEO Siddhartha Kadia on August 13, 2026, for $112.80 per share in a private transaction. After the sale, Sullivan directly holds 17,834 shares and indirectly holds 45,110 shares through the Sullivan Family Trust. The transaction was not conducted under a Rule 10b5-1 trading plan.
Mesa Laboratories (NASDAQ: MLAB) director lifts stake to 6,298 shares
Mesa Laboratories Inc. director R. Tony Tripeny recently increased his direct stake in the company by purchasing 900 shares of common stock at $113.69 per share on August 13, 2026. This transaction raised his total direct holdings to 6,298 shares. The Form 4 filing indicates this was a non-derivative, open-market purchase and not made under a Rule 10b5-1 plan.
Wasatch Advisors LP Increases Position in Mesa Laboratories, Inc. $MLAB
Wasatch Advisors LP significantly increased its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 125.8% in the second quarter, now owning 115,668 shares valued at $11.5 million. This comes as other institutional investors also adjusted their positions in the medical instruments supplier. Despite an overall "Hold" rating from analysts with an average price target of $94, the stock recently opened at $112.80, while insiders have sold shares to cover tax obligations.
Mesa Laboratories (MLAB) Stock Jumps As Margin Gains Meet Backlog Doubts
Mesa Laboratories' stock jumped 9.5% after its Q1 2027 earnings, with investors focusing on improved profitability despite modest revenue growth. Gross margins increased, and cash generation was solid, but net income and EPS declined year-on-year. The company faces risks from backlog issues and customer frustration in its largest segment, raising questions about whether the current high P/E is justified.
Mesa Laboratories, Inc. Q1 2027 Earnings Call Summary
Mesa Laboratories, Inc. is pivoting its strategy from aggressive M&A to internal execution and "self-help" to address recent underperformance, which management attributes to fixable operational issues rather than structural demand shifts. The company is focusing on strengthening its balance sheet, re-prioritizing R&D for its next-generation Gyrolab platform, and implementing cultural changes to improve efficiency and customer loyalty, particularly within its Sterilization and Disinfection Controls (SDC) and Biopharmaceutical Development (BPD) segments. Fiscal 2027 guidance is deferred, and management is working to resolve an increased SDC backlog and rebuild the BPD commercial engine.
Mesa Labs Posts Margin Surge, Pays Down $8.7 Million in Debt as New CEO Tackles Delivery Delays
Mesa Laboratories reported a 1% increase in Q1 revenue to $60.1 million, with adjusted operating income surging nearly 20% and gross margin expanding to 64.9% due to cost controls. The company generated $14.7 million in operating cash flow and repaid $8.7 million in debt, reducing its net leverage. However, its largest division, Sterilization and Disinfection Control, saw organic revenue decline due to delivery issues, which new CEO Siddhartha Kadia is prioritizing to fix.
Press Release: Mesa Labs Announces First Quarter Results
This is a press release from Mesa Labs announcing their first-quarter results. The document provided was empty, so no further summary can be generated.
Mesa Laboratories Inc (MLAB) (Q1 2027) Earnings Call Highlights: Margin Expansion and Debt ...
Mesa Laboratories Inc. (MLAB) reported its Q1 2027 earnings, showing a 1% increase in total revenue to $60.1 million and a significant 16.5% rise in adjusted operating income. The company achieved margin expansion and reduced its net leverage ratio to 1.85x by repaying $8.7 million in debt. While some segments like BPD and Calibration Solutions saw organic growth, the SDC segment experienced a revenue decline due to delivery issues, and GAAP net income decreased by 40.3% because of currency swings.
Mesa Laboratories Inc /Co/ 2026: Revenue $60.14M, EPS $0.49— 10-Q Summary
Mesa Laboratories Inc /Co/ reported its 2026 quarterly results with revenue slightly up to $60.14M from $59.54M the previous year. However, net income decreased by 40.3% to $2.83M, and diluted EPS fell by 42.4% to $0.49. The company highlighted revenue growth in Calibration Solutions and Biopharma Development, improved gross margin, and increased operating income due to cost containment.
Mesa Laboratories (MLAB) lifts Q1 margins and cash flow while net income falls
Mesa Laboratories (MLAB) reported Q1 FY2027 revenue of $60,138, a 1.0% increase year-over-year, with gross profit rising to $39,012 due to improved gross margins. Operating income more than doubled to $7,031, and operating cash flow strengthened significantly to $14,736, leading to a net debt reduction. However, net income fell to $2,830 from $4,742 in the prior year, primarily due to the non-recurrence of a foreign currency gain.
Mesa Labs Announces First Quarter Results
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced its first fiscal quarter (1Q27) results, reporting a 1.0% increase in revenues to $60,138 thousand. Non-GAAP adjusted operating income (AOI) excluding unusual items rose 19.5%, reaching 25.6% of revenues. The company also reduced its Total Net Leverage Ratio to 1.85, exceeding its target, and highlighted positive core organic growth driven by its Biopharmaceutical Development and Calibration Solutions divisions.
Mesa Labs Announces First Quarter Results
Mesa Laboratories, Inc. announced its first fiscal quarter results, showing a 1.0% increase in revenues and a 129% increase in operating income. The company reported positive core organic growth driven by its Calibration Solutions and Biopharmaceutical Development divisions, with a significant reduction in its Total Net Leverage Ratio to 1.85. Mesa's new CEO, Siddhartha Kadia, emphasized disciplined execution and profitable growth across its four divisions.
Mesa Labs Announces First Quarter Results
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced its first fiscal quarter results for 1Q27, ending June 30, 2026. The company reported a 1.0% increase in revenues and a 129% increase in operating income, driven by growth in its Calibration Solutions and Biopharmaceutical Development divisions. Mesa Labs also reduced its total net leverage ratio to 1.85, exceeding its target.
Renaissance Technologies LLC Has $2.79 Million Holdings in Mesa Laboratories, Inc. $MLAB
Renaissance Technologies LLC significantly increased its stake in Mesa Laboratories (MLAB) by 802.9% in Q1, now holding 31,600 shares valued at $2.79 million. Despite institutional ownership reaching 90.6%, the company missed Q1 analyst estimates for revenue and EPS. Analysts maintain a "Reduce" rating for MLAB, and insiders have sold shares worth approximately $770,000 recently.
Mesa Laboratories, Inc. expected to post earnings of 3 cents a share - Earnings Preview
Mesa Laboratories, Inc. (MLAB) is anticipated to report earnings of 3 cents per share. This earnings preview is based on information from Refinitiv and was published on TradingView News.
Mesa Laboratories Inc (MLAB) Earnings Forecast: Future EPS & Revenue Growth Estimates
Mesa Laboratories Inc (MLAB) has an earnings forecast score of 7.33, ranking 141st in its industry, with an average price target of $95.00 from three analysts. Analysts generally recommend a "Buy" for MLAB, anticipating next quarter's revenue at $60.87 million and EPS at $0.03.
Janus Henderson Group PLC Cuts Holdings in Mesa Laboratories, Inc. $MLAB
Janus Henderson Group PLC significantly reduced its stake in Mesa Laboratories, Inc. by 40.5% in the first quarter of 2026, selling over 47,000 shares. Despite other institutional investors increasing their holdings, company insiders sold a substantial number of shares. Mesa Laboratories also missed its quarterly earnings and revenue estimates, maintaining a "Reduce" consensus rating from analysts with an average price target of $94.
Lazard Asset Management LLC Buys New Stake in Mesa Laboratories, Inc. $MLAB
Lazard Asset Management LLC has acquired a new stake of 20,328 shares in Mesa Laboratories (MLAB), valued at approximately $1.8 million, bringing institutional ownership to 90.6% of the company. Despite missing analyst estimates for quarterly revenue and earnings, the stock recently rose by 3.6% to $104.43, though it holds a "Reduce" consensus rating and an average analyst price target of $94. Mesa Laboratories also declared a quarterly dividend of $0.16 per share, representing a 0.6% yield.
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced it will release its first fiscal quarter (1Q27) financial results, ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host its first earnings conference call on the same day at 4:30 p.m. Eastern Time, which will include a Q&A session with analysts. Details for accessing the call via toll-free number, international number, or webcast are provided in the announcement.
Mesa Labs to release Q1 2027 earnings on August 10 with a live conference call.
Mesa Labs (MSLB) will release its financial results for the first quarter of fiscal 2027, ending June 30, 2026, on August 10 after market close. The company will also host an earnings conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and answer questions. Mesa Labs is a leader in life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries.
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced it will release its first fiscal quarter financial results for the period ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host its inaugural earnings conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and conduct a Q&A session with analysts. Details for accessing the call via telephone or webcast are provided, along with information about a replay.
Mesa Labs to Hold Its First Earnings Call After Results Aug. 10
Mesa Labs (NASDAQ: MLAB) announced it will release its first fiscal quarter (1Q27) financial results, for the period ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host its inaugural earnings conference call on the same day at 4:30 p.m. Eastern Time to discuss these results and engage in a Q&A session with analysts. Investors can join the call via phone or webcast, and a replay will be available for 45 days on the Mesa Labs website.
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced it will release its first fiscal quarter (1Q27) financial results, covering the period ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host its first earnings conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and conduct a Q&A session with analysts. Details for accessing the conference call via phone or webcast have been provided.
Mesa Laboratories Inc (MLAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Mesa Laboratories Inc (MLAB), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 29, 2026, MLAB's price momentum score is 3.97, suggesting it is suitable for range-bound swing trading between resistance at 108.22 and support at 90.55. The analysis shows a mixed signal from indicators (1 sell, 5 neutral, 1 buy) but a strong buy signal from moving averages (5 buy, 1 sell for MA200).
Mesa Laboratories Inc (MLAB) Financial Health: Profitability & Balance Sheet Analysis
Mesa Laboratories Inc (MLAB) currently holds a financial score of 7.93, ranking 56th in the Healthcare Equipment & Supplies industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $63.72M, marking a 2.56% year-over-year increase, and a net profit increase of 41.86% year-over-year. Despite strong operational efficiency and growth potential, several key financial metrics like cash and cash equivalents, total assets, and free cash flow have not been disclosed by the company.
Mesa Laboratories (Nasdaq:MLAB) - Stock Analysis
This report provides a comprehensive stock analysis of Mesa Laboratories (MLAB), detailing its company overview, valuation metrics, future growth potential, past performance, financial health, dividend information, management, and ownership. Key highlights include its current trading value below fair value estimates, projected earnings growth of 30.78% per year, and recent corporate news such as dividend declarations, insider transactions, and executive appointments. The analysis also covers potential risks like interest payment coverage and recent estimate revisions.
Mesa Laboratories Inc (MLAB) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article details the historical dividend payouts for Mesa Laboratories Inc (MLAB), showing a consistent interim and final cash dividend of $0.16 per share. It lists future dividend dates including record, payment, and ex-dividend dates extending into 2026. The company has distributed a total of $16.82 million in dividends over the past five years.
